Ecovyst's Sulfur Pivot: Calabrian Closing Marks a New Era

A Pivotal Quarter for Ecovyst

Ecovyst's second-quarter 2026 report marks a genuine inflection point. The company, long a leading provider of sulfuric acid and regeneration services, has now fully pivoted into a pure-play sulfur solutions platform after divesting its Advanced Materials & Catalysts segment. The quarter brought a landmark transaction: the closure of the Calabrian acquisition, which adds sulfur dioxide and sodium metabisulfite capabilities, expanding the company's reach into mining, pharma, and industrial end uses. As CEO Kurt Bitting noted, “The quarter was also a milestone in strategic execution. On June 30, we closed the acquisition of the Calabrian sulfur dioxide and related derivatives business, the third bolt-on in a playbook we have now run 3 times.” — Kurt Bitting, Chief Executive Officer · 2026-08-05 This acquisition is not just capacity; it's a strategic extension of the company's core sulfur chemistry franchise.

The results themselves were strong. Revenue rose 11% ex-sulfur pass-through, and adjusted EBITDA climbed 27% to $53 million, “solidly within our guidance range,” according to CFO Mike Feehan. “Adjusted EBITDA of $53 million was up 27% and solidly within our guidance range.” — Michael Feehan, Chief Financial Officer · 2026-08-05 The company now expects full-year adjusted EBITDA of $195–$207 million, up from the prior $185–$195 million legacy range, with Calabrian contributing $10–$12 million in the second half.

The Calabrian Acquisition: A Platform Builder

Calabrian is the third in a series of accretive bolt-ons. Kurt and team have been transparent about the synergy potential. In a previous call, Kurt highlighted Calabrian's unique position: “They are the only on-purpose North American producer of sulfur dioxide and the only producer of sodium metabisulfite in North America.” — Kurt J. Bitting, Chief Executive Officer · 2026-05-05 The current call reaffirms $3–$4 million in cost and revenue synergies, stepping down the initial 8x purchase multiple to roughly 7x. More importantly, it deepens the company's connection to Canadian mining, which is benefiting from elevated gold prices. As Kurt put it, “we believe that sulfur is largely plateauing right now at its current levels” — Kurt Bitting, Chief Executive Officer · 2026-08-05 – a remark that underscores the cyclical tailwind the company is riding.

The company's Calabrian acquisition is a clear example of the bolt-on acquisition strategy management has honed across three transactions. Combined with the earlier Waggaman purchase, Ecovyst now operates a more interconnected Gulf Coast network, which CEO Kurt Bitting describes as "a network of essential sulfur chemistries embedded in our customers' operations."

Sulfur Prices and Market Dynamics

Sulfur prices have been a dominant theme. While they have surged, the company's contractual pass-through model protects EBITDA. Still, management expects prices to plateau. Kurt noted, “we believe that sulfur is largely plateauing right now at its current levels” — Kurt Bitting, Chief Executive Officer · 2026-08-05 – though he hedged that international prices remain elevated. The Sulfur prices keyword has been rising in the company's trajectory, and the call confirms the company's cautious optimism about demand resilience. The sulfuric acid volume grew double-digit for virgin acid, partly thanks to Waggaman, and regenerated acid volumes benefited from high refinery utilization and favorable alkylate economics.

On the demand side, mining remains a secular growth driver, supported by copper and gold projects. The company expects continued strength in regenerated sulfuric acid through the second half, with virgin acid sales expected to be stable. The company's strategic pivot to focus solely on sulfur chemistries is a reflection of this strength, as the company bets on the structural demand for sulfur-based products in a decarbonizing world.

Financial Strength and Guidance

Ecovyst's balance sheet has transformed. After using asset sale proceeds and debt reduction, the company ended Q2 with a net debt leverage ratio of 2.0x, at the low end of its 2–2.5x target. The Calabrian deal was funded with $100 million of additional term loan debt, but management plans to delever quickly. The company's effective net cash position improved dramatically as a result of the AM&C divestiture and disciplined capital allocation. Over the past 15 months, the company has executed $83 million in stock repurchases, reduced debt by $472 million, and made two acquisitions (aggregating $224 million) – all while staying within its leverage target.

In the prior quarter, management had already raised the low end of guidance, as Mike noted: “We did raise the bottom end of it, so our midpoint is up to $187.5 million.” — Michael P. Feehan, Chief Financial Officer · 2026-05-05 Now, with Calabrian in the fold, the company is guiding to $1.02–$1.06 billion in sales and adjusted free cash flow of $45–$55 million. The higher sulfur costs will impact working capital, but the company is confident in its cash generation. As Mike Feehan said, "We do believe the Calabrian acquisition is going to be cash flow positive for us."

Our advantage is not any single asset or transaction. It is a network of essential sulfur chemistries embedded in our customers' operations, a position we have now extended 3x without stretching the balance sheet.

Market Context and Valuation

Despite the strong operational results and strategic progress, Ecovyst's stock has sold off sharply, down 25% in the last 90 days. This divergence between fundamentals and price action suggests the market is focused on potential cyclical headwinds (sulfur prices rolling over, nylon weakness) or simply de-rating the specialty chemical space. The company now trades at ~1.7x trailing revenue and ~17.5x operating income. With the Calabrian acquisition expected to be accretive and the company executing its playbook, the risk-reward may be asymmetric.

In the context of global markets, Gulf Coast storage expansion is a key growth project, and the company remains committed to regenerated sulfuric acid as a core earnings driver. The next few quarters will be crucial to see whether the volume momentum can offset any potential price normalization.